Cryosite Limited's (ASX:CTE) Subdued P/E Might Signal An Opportunity
Jan 15
Have your own idea? Try our Stock Screener
Australian (ASX) Life Sciences Industry Analysis
UpdatedJan 20, 2025
DataAggregated Company Financials
Companies7
- 7D-6.9%
- 3M-23.4%
- 1Y6.6%
- YTD-11.7%
Over the last 7 days, the Life Sciences industry has dropped 6.9%, driven by pullbacks in EZZ Life Science Holdings and Trajan Group Holdings of 10% and 6.8%, respectively. In the past year, the industry has gained 6.6%. Earnings are forecast to grow by 68% annually.
Industry Valuation and Performance
Has the Australian Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Mon, 20 Jan 2025 | AU$559.3m | AU$253.8m | -AU$57,118,384.00 | 17.5x | -9.8x | 2.2x |
| Wed, 18 Dec 2024 | AU$620.1m | AU$263.5m | -AU$69,135,603.00 | 21.5x | -9x | 2.4x |
| Fri, 15 Nov 2024 | AU$657.9m | AU$263.5m | -AU$69,135,603.00 | 21.1x | -9.5x | 2.5x |
| Sun, 13 Oct 2024 | AU$716.3m | AU$263.5m | -AU$69,135,603.00 | 24.8x | -10.4x | 2.7x |
| Tue, 10 Sep 2024 | AU$690.4m | AU$263.3m | -AU$69,597,222.00 | 19.4x | -9.9x | 2.6x |
| Thu, 08 Aug 2024 | AU$610.4m | AU$246.1m | -AU$49,506,434.00 | 22.7x | -12.3x | 2.5x |
| Sat, 06 Jul 2024 | AU$594.7m | AU$246.1m | -AU$49,506,434.00 | 29.4x | -12x | 2.4x |
| Mon, 03 Jun 2024 | AU$546.4m | AU$246.1m | -AU$49,506,434.00 | 23.4x | -11x | 2.2x |
| Wed, 01 May 2024 | AU$554.3m | AU$246.1m | -AU$49,506,434.00 | 18.9x | -11.2x | 2.3x |
| Fri, 29 Mar 2024 | AU$539.1m | AU$246.1m | -AU$49,506,434.00 | 14.3x | -10.9x | 2.2x |
| Sun, 25 Feb 2024 | AU$505.1m | AU$243.2m | -AU$44,302,241.00 | 19.5x | -11.4x | 2.1x |
| Tue, 23 Jan 2024 | AU$476.8m | AU$248.2m | -AU$39,797,313.00 | 25.8x | -12x | 1.9x |
| Thu, 21 Dec 2023 | AU$521.0m | AU$248.6m | -AU$52,451,569.00 | 21.8x | -9.9x | 2.1x |
| Sat, 18 Nov 2023 | AU$543.8m | AU$248.6m | -AU$52,451,569.00 | 22.3x | -10.4x | 2.2x |
| Mon, 16 Oct 2023 | AU$559.1m | AU$248.6m | -AU$52,451,569.00 | 22.3x | -10.7x | 2.2x |
| Wed, 13 Sep 2023 | AU$585.2m | AU$248.6m | -AU$52,451,569.00 | 22.7x | -11.2x | 2.4x |
| Fri, 11 Aug 2023 | AU$641.3m | AU$221.5m | -AU$37,611,177.00 | 25.2x | -17.1x | 2.9x |
| Sun, 09 Jul 2023 | AU$653.0m | AU$221.5m | -AU$37,611,177.00 | 25.2x | -17.4x | 2.9x |
| Tue, 06 Jun 2023 | AU$633.2m | AU$221.5m | -AU$37,611,177.00 | 21.5x | -16.8x | 2.9x |
| Thu, 04 May 2023 | AU$627.5m | AU$221.5m | -AU$37,611,177.00 | 30.6x | -16.7x | 2.8x |
| Sat, 01 Apr 2023 | AU$722.0m | AU$221.7m | -AU$39,169,534.00 | 30.2x | -18.4x | 3.3x |
| Mon, 27 Feb 2023 | AU$781.6m | AU$174.6m | -AU$40,998,286.00 | 30.2x | -19.1x | 4.5x |
| Wed, 25 Jan 2023 | AU$812.7m | AU$184.6m | -AU$29,264,632.00 | 35.1x | -27.8x | 4.4x |
| Fri, 23 Dec 2022 | AU$787.0m | AU$184.6m | -AU$29,264,632.00 | 33.1x | -26.9x | 4.3x |
| Sun, 20 Nov 2022 | AU$761.0m | AU$184.6m | -AU$29,264,632.00 | 30.3x | -26x | 4.1x |
| Tue, 18 Oct 2022 | AU$782.4m | AU$184.6m | -AU$29,264,632.00 | 31.3x | -26.7x | 4.2x |
| Thu, 15 Sep 2022 | AU$856.5m | AU$184.6m | -AU$29,264,632.00 | 36.8x | -29.3x | 4.6x |
| Sat, 13 Aug 2022 | AU$960.8m | AU$150.4m | -AU$31,222,532.00 | 28.2x | -30.8x | 6.4x |
| Mon, 11 Jul 2022 | AU$878.5m | AU$150.4m | -AU$31,222,532.00 | 28.4x | -28.1x | 5.8x |
| Wed, 08 Jun 2022 | AU$956.2m | AU$150.4m | -AU$31,222,532.00 | 28.9x | -30.6x | 6.4x |
| Fri, 06 May 2022 | AU$1.1b | AU$150.2m | -AU$30,481,316.00 | 27.2x | -37.4x | 7.6x |
| Sun, 03 Apr 2022 | AU$1.2b | AU$167.1m | -AU$90,069,489.00 | 19.9x | -13.3x | 7.2x |
| Tue, 01 Mar 2022 | AU$1.3b | AU$173.3m | -AU$89,816,993.00 | 19.1x | -15x | 7.8x |
| Thu, 27 Jan 2022 | AU$1.7b | AU$138.2m | -AU$84,243,063.00 | 105.2x | -19.8x | 12.1x |
Price to Earnings Ratio
-19.8x
Current Industry PE
- Investors are pessimistic on the Australian Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
- The 3-year average PS ratio of 3.8x is higher than the industry's current PS ratio of 2.2x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have improved over the last three years.
- Revenues for these companies have grown 22% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Australian Healthcare industry?
| AU Market | 0.10% | |
| Healthcare | -2.45% | |
| Life Sciences | -6.86% | |
| Clinical Research and Equipment | -6.86% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| PIQ Proteomics International Laboratories | AU$0.69 | 0.7% +AU$655.0k | -24.2% | PS27.6x |